Live

P

$PTGX

2 articles found

1 positive

0 negative

1 neutral

J&J and Protagonist Win FDA Approval for Oral Psoriasis Drug, Challenging AbbVie's Market Dominance

Benzinga

Benzinga·5d ago·Vandana Singh

J&J and Protagonist Win FDA Approval for Oral Psoriasis Drug, Challenging AbbVie's Market Dominance

FDA approves Icotyde for psoriasis, triggering $50M payment to Protagonist. Market reacts with AbbVie stock falling 5.20% amid competitive pressure.

JNJABBVPTGXFDA approvalplaque psoriasis

Major Hedge Fund Exits Protagonist Position Despite 120% Stock Surge

The Motley Fool

The Motley Fool·Feb 25·Jonathan Ponciano

Major Hedge Fund Exits Protagonist Position Despite 120% Stock Surge

BVF Partners liquidated its $170M Protagonist stake despite 120% gains, likely due to changing risk profile as company awaits FDA decision on blood disorder treatment.

PTGXKYMRRVMDRVMDWclinical-stage biotechhedge fund liquidation